Abdera Therapeutics
Courteney Lai currently serves as a Senior Scientist at Abdera Therapeutics, with a previous role as Research Scientist at AbCellera, where significant contributions included developing cell-based assays for antibody functions and leading projects that narrowed candidate selections for therapeutic development. Prior experience includes postdoctoral positions at Hannover Medical School and BC Cancer, focusing on acute myeloid leukemia and drug sensitivity. Courteney's academic background includes a PhD in Experimental Medicine and dual Bachelor's degrees in Cell Biology & Genetics and Psychology from The University of British Columbia. Key skills encompass human cell line models, cytotoxicity assays, flow cytometry, and lentiviral transduction. Courteney is also recognized for leadership through participation in the Foundational Leadership Program at AbCellera and co-founding a Flow Cytometry Community of Practice within the organization.
This person is not in any teams
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.